title: [Clinical observations of ductal carcinoma in situ and early stage breast cancer with invasive depth less than 1 cm].
abstract: OBJECTIVE
  To explore the clinical characteristics and prognosis of ductal carcinoma in situ (DCIS) and early stage ductal breast cancer with invasive depth ≤ 1 cm.
  
  
  METHODS
  Follow-up analyses were performed for the clinical data of 57 patients with DCIS, 46 with pT(1mic) and 74 with pT(1a-b) breast cancer treated or consulted at our hospital. Single factor analysis was used to examine their prognostic factors.
  
  
  RESULTS
  Among them, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2(HER-2) positive rate and visual tumor size (2.0(0.1-7.0) vs 2.0(0.5-10.0) vs 2.0(0.3-10.0) cm)had no statistical differences between 3 groups (all P > 0.05). After median follow-up periods of 63, 38, 59 months, 12 patients suffered recurrence and metastasis and the rate of each group had no statistical differences. For pT(1a-b) patients with positive hormone receptor, endocrine therapy markedly reduced the risk of recurrence and metastasis (P = 0.024) . pT(1mic), pT(1a-b) patients on chemotherapy had higher or comparable recurrence rate versus those without. And DCIS patients on chemotherapy had a much higher recurrence rate (P = 0.016) . In pT(1a-b) group, HER-2 positive patients had higher recurrence and metastasis rates. Yet there was a decreasing tendency after Herceptin treatment.
  
  
  CONCLUSIONS
  Chemotherapy without proper indications may not improve the prognosis of DCIS, pT(1mic) and pT(1a-b) patients. Endocrine therapy is the crucial prognostic factor of patients with positive hormone receptor. Use of Herceptin for HER-2-positive patients is probably significant.
authors.affiliation: Department of Breast Cancer, No. 307 Hospital of PLA, Beijing 100071, China.
authors.forename: Chang
authors.initials: C
authors.lastname: You
authors.affiliation: Email: songsantai2006@163.com.
authors.forename: Santai
authors.initials: S
authors.lastname: Song
authors.forename: Shikai
authors.initials: S
authors.lastname: Wu
authors.forename: Xiaobing
authors.initials: X
authors.lastname: Li
authors.forename: Lijuan
authors.initials: L
authors.lastname: Ding
authors.forename: Zefei
authors.initials: Z
authors.lastname: Jiang
authors.forename: Chengze
authors.initials: C
authors.lastname: Yu
authors.forename: Yan
authors.initials: Y
authors.lastname: Huang
mesh_terms: D000328:Adult; D000368:Aged; D001943:Breast Neoplasms / Q000175:diagnosis / Q000473:pathology*; D002278:Carcinoma in Situ / Q000175:diagnosis / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000175:diagnosis / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases
chemical_list: D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human